2 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
Follow HER2: new trials by email Literature Review of HER2 trials Research Report on HER2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors CGT4255 - Advanced Solid Tumor, Adult, ERBB2 Altered Breast Cancer | Phase 1 | Recruiting | Cogent Biosciences, Inc. | 100 | 2025-12-30 | 2026-09-04 |
| A Phase 1/1b Study of IAM1363 in HER2 Cancers IAM1363 - HER2 Mutation-Related Tumors, HER2 | Phase 1 | Recruiting | Iambic Therapeutics, Inc | 383 | 2024-03-25 | 2026-09-09 |
Carcinoma, Non-Small-Cell Lung (2) · Brain Neoplasms (1) · Breast Neoplasms (1) · Neoplasms (1) · Stomach Neoplasms (1)
Bronchial Neoplasms (2) · Carcinoma, Bronchogenic (2) · Lung Diseases (2) · Lung Neoplasms (2) · Neoplasms by Site (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Thoracic Neoplasms (2) · Brain Diseases (1) · Breast Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1)
Cogent Biosciences, Inc. (1) · Iambic Therapeutics, Inc (1)
United States (2) · France (1) · Ireland (1) · Italy (1) · Netherlands (1) · South Korea (1) · Spain (1) · United Kingdom (1)